Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2019 - 2026)

Zentalis Pharmaceuticals has reported Accumulated Expenses for 8 years, with the latest figure at $27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 33.13% year-over-year to $27.9 million; the trailing twelve-month figure through Mar 2026 stood at $27.9 million (down 33.13% YoY), and the FY2025 full-year result was $29.4 million, down 35.19% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $27.9 million, down from $29.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $54.4 million in Q4 2023, with the low at $27.9 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $40.3 million, with a median of $43.5 million recorded in 2023.
• Year-over-year, Accumulated Expenses soared 44.62% in 2022 and sank 35.43% in 2025.
• Tracing ZNTL's Accumulated Expenses over 5 years: stood at $45.4 million in 2022, then advanced by 19.91% to $54.4 million in 2023, then slipped by 16.81% to $45.3 million in 2024, then sank by 35.19% to $29.4 million in 2025, then dropped by 5.09% to $27.9 million in 2026.
• The last three Accumulated Expenses figures came in at $27.9 million (Q1 2026), $29.4 million (Q4 2025), and $30.1 million (Q3 2025), per Business Quant data.

Peer Comparison